SAPIEN 3 TRANSCATHETER HEART VALVE AND ACCESSORIES
Edwards Lifesciences, LLC · Decision date Jun 17, 2015
What did the FDA approve?
FDA records P140031 as an original PMA application. The recorded decision is approval, dated Jun 17, 2015.
FDA approval order statement
APPROVAL FOR THE EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE, MODEL 9600TFX, AND ACCESSORIES. THIS DEVICE IS INDICATED FOR RELIEF OF AORTIC STENOSIS IN PATIENTS WITH SYMPTOMATIC HEART DISEASE DUE TO SEVERE NATIVE CALCIFIC AORTIC STENOSIS WHO ARE JUDGED BY A HEART TEAM, INCLUDING A CARDIAC SURGEON, TO BE AT HIGH OR GREATER RISK FOR OPEN SURGICAL THERAPY (I.E., SOCIETY OF THORACIC SURGEONS OPERATIVE RISK SCORE 8% OR AT A 15% RISK OF MORTALITY AT 30 DAYS).
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Jun 17, 2015
Regulatory record facts
- Identifier
- P140031
- Regulatory pathway
- Premarket approval application
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPT
- Decision code
- APPR
- Decision date
- Jun 17, 2015
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Aortic valve, prosthesis, percutaneously delivered.
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPT
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P140031 received
Application receipt date recorded by FDA.
P140031 · FDA decision
APPR
P140031/S209 · Related supplement
Edwards Crimper (9600LDS23, 9600LDS26, 9600LDS29, 9750CM20, 9750CM23, 9750CM26, 9750CM29)
P140031/S202 · Related supplement
Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve
P140031/S210 · Related supplement
Edwards SAPIEN 3 Transcatheter Heart Valve (9600TFX), Edwards SAPIEN 3 Ultra Transcatheter Heart Valve (9750TFX)
Timeline entries are records held by MedtechLedger for P140031. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P140031
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Edwards Lifesciences, LLC | PMA supplement | Sep 23, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 22, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA |
Explore the linked device profile
Other records with product code NPT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Nov 7, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 29, 2026 | FDA | |
Trilogy Transcatheter Heart Valve SystemP250024/S005 | JenaValve Technology, Inc. | PMA supplement | Oct 13, 2026 | FDA |
Trilogy Transcatheter Heart Valve SystemP250024/S006 | JenaValve Technology, Inc. | PMA supplement | Oct 7, 2026 | FDA |
| JenaValve Technology, Inc. | PMA approval | Mar 17, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Edwards Lifesciences, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- One Edwards Way, Irvine, CA, 92614
Sources and methodology
- Original FDA record: P140031
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
